Market News & Trends
QUANTRO Therapeutics Achieves Breakthrough in Transcriptomic Drug Discovery
QUANTRO Therapeutics recently announced it has successfully completed its first ten-target multiplex-screening campaign, which yielded validated hits and functional proof of on-target activity for multiple…
Phillips Medisize Expands Its Inhalation Drug Delivery Capabilities
Molex, a parent to Phillips Medisize, recently announced it has completed, through an affiliate, the previously announced acquisition of Vectura Group Ltd. (Vectura) from Vectura…
Fortress Biotech & Cyprium Therapeutics Announce FDA Acceptance & Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
Fortress Biotech, Inc. and its majority-owned subsidiary, Cyprium Therapeutics, Inc. recently announced the acceptance for review of the New Drug Application (NDA) by the US…
Nuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio Inc. recently announced China’s National Medical Products Administration (NMPA) has approved taletrectinib for the treatment of adult patients with locally advanced or metastatic…
Gaelic Laboratories Announces Expansion Enabling Access to Growing Middle East Market
Gaelic Laboratories has established a subsidiary in the UAE, enabling access to the Middle East market – both for Gaelic Laboratories and its marketing partners…
Atavistik Bio Announces Research Collaboration With Pfizer
Atavistik Bio recently announced it has entered into a research collaboration with Pfizer to accelerate the discovery of novel precision allosteric therapeutics to address significant…
ACELYRIN to Share New Phase 2 Data & Phase 3 Program Design for Subcutaneous Lonigutamab
ACELYRIN, INC. recently announced it will host a virtual investor event on Monday, January 6, 2025 at 4:30 PM ET to provide updated Phase 2…
Immuno-Oncology/Cancer Therapeutics Present Strongest Innovation Pipeline in Next 5 Years
Immuno-oncology (IO) drugs/cancer therapeutics represent one of the most promising areas of medical innovation in the next five years, fundamentally transforming how cancer is treated,…
Eton Pharmaceuticals Advances its Commitment to Rare Disease With Acquisition
Eton Pharmaceuticals, Inc recently announced it has acquired Galzin (zinc acetate). “This acquisition furthers our mission of supporting life-saving treatments for conditions impacting ultra rare…
TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs
TNF Pharmaceuticals, Inc. recently announced it has entered into a collaborative agreement with Renova Health for a planned trial of its TNF-alpha (TNF-α) inhibitor drug…
Recognition of the American Society of Clinical Oncology of the Liver Protective Effect of Can-Fite’s Anti-Cancer Drug Namodenoson
Can-Fite BioPharma Ltd. recently announced that its work titled The Liver Protective Effect of the Anti-Cancer Drug Candidate Namodenoson is Mediated via Adiponectin will be presented…
OBI Pharma Enters Collaboration With GlyTech to Expand GlycOBI Enabling Technologies Outreach in Japan & to Advance Glycan Production
OBI Pharma, Inc. and GlyTech, Inc. have entered into a Marketing Agreement and a Material Transfer Agreement. Under the terms of the Marketing Agreement, OBI…
CORXEL Acquires Worldwide (excluding Greater China) Rights to an Oral Small Molecule for the Treatment of Obesity & Diabetes
Corxel Pharmaceuticals recently announced the acquisition of CX11 (also known as VCT220), an oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA), for worldwide (excluding…
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity
Wave Life Sciences Ltd. recently announced the submission of its first clinical trial application (CTA) for WVE-007 in obesity. WVE-007 is an investigational GalNAc-conjugated small…
Ikena Oncology & Inmagene Biopharmaceuticals Announce Agreement for Merger & Private Placement
Ikena Oncology, Inc. and Inmagene Biopharmaceuticals recently announced they have entered into a definitive merger agreement. In connection with the merger, Ikena has entered into…
GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 & its Library of 500+ Proprietary Compounds
GRI Bio, Inc. recently announced the European Patent Office (EPO) has issued a decision to grant notice for patent application number 19,166,502 titled, Oxygenated Amino-…
Apollomics Announces Top-line Results for Phase 3 Trial of Uproleselan in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Apollomics Inc. recently announced the results from its Phase 3 bridging trial of uproleselan in China in patients with relapsed or refractory acute myeloid leukemia.…
Lonza Capsules & Health Ingredients Expands Capsule Manufacturing Capacity in India & China
Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, today announced capacity expansions at its sites in Rewari (IN) and Suzhou (CN).…
Shuttle Pharma Enters Sponsored Research Agreement With the University of California, San Francisco to Advance PSMA Development Program
Shuttle Pharmaceuticals Holdings, Inc. recently announced a sponsored research agreement with the University of California, San Francisco (UCSF) to advance pre-clinical development of Shuttle Diagnostics,…
Assembly Biosciences Announces $30.1 Million Investment & Accelerated Funding From Gilead
Assembly Biosciences, Inc. recently announced an equity investment of $20.1 million by Gilead Sciences, Inc. to purchase additional Assembly Bio common stock and an amendment…
